reports
Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides...
Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Entered into an Agreement to be acquired by QOL Medical Net product sales for the third quarter of 2025 reached $4.3 million; up 61% year-over-year Gimoti patent life for Gimoti extended through November 2038 SOLANA BEACH, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal spray, today reported financial results for the third ...
Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Me...
Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash Represents a 139.7% premium to most recent Nasdaq closing price Transaction expected to close by the end of 2025 SOLANA BEACH, Calif., and VERO BEACH, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) (“Evoke”), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and QOL Medical, LLC (“QOL Medical”)...
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and O...
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, together with EVERSANA, a leading pro...
Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Boo...
Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI® (metoclopramide) nasal spray in patients with moderate to severe symptoms of gastroparesis, has been listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Products with Therapeutic...
Evoke Pharma Reports Second Quarter 2025 Financial Results and Provide...
Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update Q2 2025 Net Product Sales Increased 47% Year-over-Year to $3.8 Million SOLANA BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal spray, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “This quarter's results demonstrate the commercial strength of GIMOTI and the prec...
Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Ext...
Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038 Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection SOLANA BEACH, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the official issuance of a new U.S. patent related to its product GIMOTI®. The patent, U.S. Patent No. 12,37...
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application ...
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 Extends patent exclusivity period an additional 6 years once granted SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application cover...
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides...
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. “We’re pleased to report continu...
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidenc...
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025 SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 202...
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial...
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 ...
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on Ma...
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025 SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes. Management will host a conference call and webcast with accompanying slides on Thursday, March 13, 2025, at 4:...
Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Boar...
Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke’s commercial strategy and...
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis...
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMO...
Evoke Pharma Receives Notices of Allowance for Two Additional US Paten...
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, further expanding the company’s robust intellectual property estate for its innovative GIMOTI® (met...
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription fill increase; 39% increase since Q1 2024 Real-world data presented at ACG 2024 demonstrates that GIMOTI significantly enhanced outcomes for patients on GLP-1 therapy, marking it as a promising supportive care option compared to oral metoclopramide. SOLANA BEACH, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- E...
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement...
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency Department Visits (-91%, p=0.001), All Cause Office Visits (-41%, p=0.027) and All Cause Hospital Outpatient Visits (-89%, p=0.032) within 6-month index period Data presented at American College of Gastroenterology (ACG) 2024; the...
Evoke Pharma to Showcase Award-Winning Research at the 2024 American C...
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced upcoming poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, held from October 25-29, 2024. Evoke will feature two poster presentations highlighting the use of Gimoti...
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Di...
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve on the Company’s Board of Directors effective October 18, 2024. This appointment fulfills a condition set as part of the company’s most recent financing by Nantahala Capital Management. Mr. Smeal brings extensive experience in investm...
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expan...
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it received approximately $3.0 million in gross proceeds from the amendment and exercise of existing warrants. ...
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis A...
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, reaffirms its commitment to improving the lives of patients suffering from diabetic gastroparesis in light of the recent decision by the U.S. Food and Drug Administr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.